Affinage

ENO1

Alpha-enolase · UniProt P06733

Length
434 aa
Mass
47.2 kDa
Annotated
2026-06-09
100 papers in source corpus 47 papers cited in narrative 47 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ENO1 is a metabolic glycolytic enzyme that converts 2-phosphoglycerate to phosphoenolpyruvate, and whose enzymatic activity, abundance, and moonlighting functions are extensively co-opted to drive aerobic glycolysis, tumor progression, and inflammatory/fibrotic remodeling across diverse tissues (PMID:36815049, PMID:33230295). The single ENO1 locus generates two functionally distinct products: a cytoplasmic 48 kDa α-enolase and a 37 kDa nuclear form (MBP-1) produced via an alternatively transcribed intron III mRNA, which binds the c-myc P2 promoter and represses c-myc transcription (PMID:10802057, PMID:20849415). Beyond glycolysis, ENO1 acts as a sequence-selective RNA-binding protein that controls the fate of target transcripts—recruiting the deadenylase CNOT6 to accelerate IRP1 mRNA decay and thereby restrain ferroptosis (PMID:35121990), binding CUG-rich elements of YAP1 mRNA to promote its translation and downstream prostaglandin signaling (PMID:37500770), and stabilizing 3'UTR-bound mRNAs such as KLF2 to limit NLRP3 inflammasome-mediated pyroptosis (PMID:39467260). ENO1 enzymatic activity is tuned by post-translational modifications: PRMT5/PRMT6 methylation at R9 promotes active dimer formation while R372 methylation enhances substrate binding (PMID:36815049, PMID:36999124), and CBP-written, SIRT2-erased K420 crotonylation augments catalysis (PMID:34547627). ENO1 protein stability is set by a ubiquitination/deubiquitination balance, with FBXW7 and NEDD4L driving proteasomal degradation (PMID:26097998, PMID:35316145) and USP21, USP46, and UCHL3 stabilizing the protein to sustain glycolysis (PMID:32707136, PMID:38385089, PMID:40487654). Extracellular and cell-surface ENO1 functions as a plasminogen receptor and interacts with HGFR to engage Wnt/β-catenin, PI3K-AKT, ERK, STAT3, and HIF-1α signaling that collectively drive EMT, invasion, metastasis, immune evasion, and drug resistance (PMID:34145039, PMID:39752908, PMID:38897160). ENO1 is the target of collateral-lethality therapeutics: in ENO1-deleted glioma, ENO2 dependency renders cells selectively vulnerable to the enolase inhibitor POMHEX (PMID:33230295).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2000 High

    Established that the ENO1 locus is functionally bifunctional, encoding both a cytoplasmic glycolytic enzyme and a distinct nuclear transcriptional repressor, reframing ENO1 as more than a metabolic gene.

    Evidence Alternative translation analysis with α-enolase/GFP chimeras, subcellular localization, and luciferase reporter assays of MBP-1 binding the c-myc P2 promoter

    PMID:10802057

    Open questions at the time
    • Did not resolve whether MBP-1 arises from alternative translation versus a separate transcript
    • Endogenous occupancy of the c-myc promoter not shown
  2. 2010 High

    Resolved the origin of MBP-1, showing it derives from an alternatively transcribed intron III mRNA that is far more efficient at producing the repressor and is induced by hypoxia.

    Evidence MBP-1 promoter luciferase reporters, cell fractionation with RT-PCR, coupled transcription/translation, and MG132 proteasome inhibition

    PMID:20849415

    Open questions at the time
    • Trans-factors driving hypoxic MBP-1 induction not identified
    • Relative in vivo contribution of MBP-1 versus full-length ENO1 to c-myc repression unquantified
  3. 2008 Medium

    Linked ENO1/MBP-1 abundance to MYC oncoprotein levels and proliferation, providing a regulatable handle (retinoic acid–driven dephosphorylation) on the ENO1-MYC axis.

    Evidence 2D-DIGE/MS phosphoprotein identification, siRNA knockdown, and proliferation assays in follicular thyroid carcinoma

    PMID:19060179

    Open questions at the time
    • Kinase/phosphatase responsible for ENO1-A1 dephosphorylation not defined
    • Mechanism connecting phosphostate to product levels unclear
  4. 2015 High

    Identified the first stability control point for ENO1 protein and a developmental role, showing FBXW7-mediated degradation restrains glycolysis while ENO1 is required for Wnt-driven epithelial trans-differentiation.

    Evidence Reciprocal Co-IP, ubiquitination assays, and functional cell assays (FBXW7); proteomics with siRNA in primary ATII cells and bleomycin lung injury model

    PMID:26035385 PMID:26097998

    Open questions at the time
    • Degron/phosphodegron recognized by FBXW7 not mapped
    • Whether trans-differentiation requires glycolytic versus moonlighting ENO1 unresolved
  5. 2017 High

    Defined a surface/adhesion role, showing ENO1 governs integrin and uPAR signaling to suppress ROS and senescence, distinct from its enzymatic function.

    Evidence shRNA silencing, confocal and atomic force microscopy, adhesion/invasion assays, and xenografts in pancreatic cancer

    PMID:28086938

    Open questions at the time
    • Direct physical interaction of ENO1 with integrin/uPAR not biochemically demonstrated
    • Causal step linking ENO1 to integrin transcription unknown
  6. 2021 High

    Established ENO1 as a sequence-selective RNA-binding protein that actively shapes the transcriptome, recruiting a deadenylase to destabilize a specific mRNA and thereby controlling ferroptosis.

    Evidence RNA immunoprecipitation, RNA decay assays, and in vitro/in vivo ferroptosis readouts in hepatocellular carcinoma (IRP1/CNOT6/Mfrn1)

    PMID:35121990

    Open questions at the time
    • RNA-binding domain/motif within ENO1 not mapped
    • Generality of CNOT6 recruitment beyond IRP1 untested
  7. 2021 High

    Defined membrane-receptor and signaling cascades downstream of ENO1, showing it engages HGFR to activate Src-PI3K-AKT-Wnt and drive EMT in metastasis.

    Evidence Co-IP, phosphorylation assays, orthotopic and tail-vein mouse models, and anti-ENO1 antibody studies in lung cancer

    PMID:34145039

    Open questions at the time
    • Stoichiometry and direct binding interface between ENO1 and HGFR unresolved
    • Whether intracellular versus surface ENO1 mediates HGFR activation unclear
  8. 2022 High

    Mapped post-translational control of ENO1 catalysis, showing arginine methylation drives active dimer formation and substrate binding while lysine crotonylation enhances enzymatic activity.

    Evidence Site-directed mutagenesis, in vitro methylation/crotonylation assays, enzymatic activity and glycolytic flux measurements (PRMT6 R9/R372; CBP/SIRT2 K420)

    PMID:34547627 PMID:36815049

    Open questions at the time
    • Crosstalk between distinct PTMs on the same molecule untested
    • Structural basis of dimerization change from R9 methylation not solved
  9. 2023 High

    Extended ENO1 RNA-binding to translational activation, showing it binds CUG-rich elements of YAP1 mRNA to promote translation and arachidonic acid/PGE2 signaling, and reinforced PRMT5-driven dimer activation under high glucose.

    Evidence RIP, translation assays, and in vitro/in vivo functional experiments in hepatocellular carcinoma (YAP1); dimethylation and dimerization assays in ovarian cancer (PRMT5 R9)

    PMID:36999124 PMID:37500770

    Open questions at the time
    • How ENO1 switches between mRNA decay and translational activation modes is unknown
    • Signal coupling glucose to PRMT5-ENO1 methylation incompletely defined
  10. 2024 Medium

    Layered upstream mRNA modification control onto ENO1, showing m6A (METTL3/RBM15-YTHDF1), m5C (NSUN2/YBX1), and ac4C (NAT10) marks on ENO1 mRNA enhance its translation/stability to boost glycolysis, and identified a deubiquitinase network (USP21, UCHL3) stabilizing ENO1 protein.

    Evidence m6A/m5C/ac4C site mapping, RIP, reporter and ubiquitination assays, and in vitro/in vivo functional assays across multiple cancers

    PMID:35078505 PMID:38385089 PMID:38769664 PMID:39948547 PMID:40487654

    Open questions at the time
    • Functional hierarchy among the multiple mRNA modifications unresolved
    • Several writer/reader links validated in single labs without reciprocal confirmation
  11. 2025 High

    Demonstrated direct enzymatic regulation of ENO1 by a receptor protein in immune cells, showing IL1R2 binding suppresses ENO1 activity to dampen glycolysis-driven pyroptosis and inflammation.

    Evidence Proteomic screen, Co-IP, enzymatic activity assays, IL1R2-knockout mice, and ENO1 inhibitor rescue in a sepsis model

    PMID:40704655

    Open questions at the time
    • Structural basis of IL1R2-mediated enzymatic inhibition not solved
    • Whether this regulation operates in tumor settings untested
  12. 2019 High

    Validated ENO1 as a therapeutic vulnerability via collateral lethality, showing ENO1-deleted tumors depend on ENO2 and are selectively killed by an enolase inhibitor.

    Evidence In vitro killing assays, intracranial orthotopic xenografts, and non-human primate pharmacokinetics (POMHEX)

    PMID:33230295

    Open questions at the time
    • Applicability beyond ENO1-deleted gliomas unestablished
    • Selectivity for ENO1 versus ENO2 in non-deleted tissues not addressed here

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ENO1 partitions between its glycolytic, nuclear (MBP-1), RNA-binding, and cell-surface/plasminogen-receptor functions—and what governs the switch—remains unresolved.
  • No structural definition of the RNA-binding interface
  • Determinants of cytoplasmic versus nuclear versus surface localization unknown
  • Integrated model reconciling moonlighting roles in a single cell lacking

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 4 GO:0016829 lyase activity 2 GO:0140110 transcription regulator activity 2 GO:0001618 virus receptor activity 1
Localization
GO:0005886 plasma membrane 3 GO:0005576 extracellular region 2 GO:0005634 nucleus 2 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-8953854 Metabolism of RNA 3 R-HSA-1430728 Metabolism 2 R-HSA-5357801 Programmed Cell Death 2 R-HSA-74160 Gene expression (Transcription) 2
Partners
CNOT6FBXW7HGFRIL1R2NEDD4LPLGPRMT5USP21

Evidence

Reading pass · 47 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2000 The ENO1 gene encodes two protein products via alternative translation initiation: a 48 kDa alpha-enolase localized predominantly in the cytoplasm, and a 37 kDa shorter form (MBP-1) that localizes preferentially to the nucleus, binds the c-myc P2 promoter consensus sequence, and downregulates c-myc transcription as demonstrated by luciferase reporter assay. Alternative translation analysis, alpha-enolase/GFP chimera transfection with subcellular localization, luciferase reporter assay with MBP-1 consensus binding sequence FEBS letters High 10802057
2010 MBP-1 is encoded by an alternatively transcribed mRNA from intron III of the ENO1 gene (not solely by alternative translation of the full-length ENO1 mRNA). This MBP-1 transcript is 17.8-fold more efficient for MBP-1 protein production than the ENO1 transcript. MBP-1 protein stability is regulated by proteasomal degradation (stabilized by MG132). Hypoxia significantly increases transcriptional activation of the MBP-1 gene. MBP-1 promoter-driven luciferase reporter assays, biochemical cell fractionation with RT-PCR, coupled transcription/translation reactions, proteasome inhibitor (MG132) treatment The FEBS journal High 20849415
2021 ENO1 functions as an RNA-binding protein that recruits the deadenylase CNOT6 to accelerate mRNA decay of iron regulatory protein 1 (IRP1) in hepatocellular carcinoma cells. This leads to inhibition of mitoferrin-1 (Mfrn1) expression and subsequent repression of mitochondrial iron-induced ferroptosis. RNA immunoprecipitation, in vitro and in vivo experiments, RNA decay assays, functional knockdown/overexpression with ferroptosis readouts Nature cancer High 35121990
2023 ENO1, acting as an RNA-binding protein, binds to cytosine-uracil-guanine-rich elements of YAP1 mRNA to promote its translation, thereby activating arachidonic acid metabolism via the YAP1/PLCB1/HPGD axis and subsequent prostaglandin E2 accumulation, which drives hepatocellular carcinoma progression. RNA immunoprecipitation, mRNA translation assays, in vitro and in vivo functional experiments, clinical sample analysis Nature chemical biology High 37500770
2021 ENO1 promotes lung cancer metastasis by interacting with hepatocyte growth factor receptor (HGFR) and activating HGFR and Wnt signaling via increased phosphorylation of HGFR and the Wnt co-receptor LRP5/6. This decreases GSK3β activity via Src-PI3K-AKT signaling and inactivates the β-catenin destruction complex, ultimately upregulating SLUG and β-catenin to drive EMT. Co-immunoprecipitation, phosphorylation assays, knockdown/overexpression with phenotypic readouts, orthotopic and tail-vein injection mouse models, anti-ENO1 antibody functional studies Cancer research High 34145039
2017 ENO1 controls alphav/beta3 integrin expression in pancreatic ductal adenocarcinoma (PDA) cells. ENO1 silencing downregulates alphav/beta3 integrin, increases RGD-independent adhesion to vitronectin via uPAR, triggers ERK1-2 and RAC activation, ROS accumulation, and cellular senescence. Anti-uPAR antibody reduces ROS and senescence in ENO1-silenced cells. shRNA-mediated ENO1 silencing, confocal microscopy, atomic force microscopy, functional adhesion/invasion assays, mouse xenograft model Journal of hematology & oncology High 28086938
2015 FBXW7 physically binds to ENO1 and targets it for ubiquitin-mediated proteasomal degradation, thereby suppressing ENO1-induced lactate production, cell proliferation, and migration in colorectal cancer. Co-immunoprecipitation, ubiquitination assay, 2D protein electrophoresis/mass spectrometry, Western blotting, functional cell assays Laboratory investigation High 26097998
2022 PRMT6 methylates ENO1 at R9 and R372: R9 methylation promotes active ENO1 dimer formation and R372 methylation promotes 2-phosphoglycerate (2-PG) substrate binding to ENO1, thereby increasing glycolytic activity in lung cancer cells. In vitro methylation assays, mutational analysis of methylation sites, enzymatic activity assays, glycolysis flux measurements Acta pharmaceutica Sinica. B High 36815049
2023 PRMT5 symmetrically dimethylates ENO1 at arginine 9 (R9) to promote active ENO1 dimer formation, increasing glycolysis flux and accelerating ovarian cancer tumor growth. PRMT5 signals high glucose to increase ENO1 methylation. In vitro dimethylation assays, co-immunoprecipitation, ENO1 dimerization assays, glycolysis flux measurement, knockdown/inhibitor studies in vitro and in vivo MedComm High 36999124
2021 Lysine crotonylation (Kcr) of ENO1 is elevated in colorectal cancer. CBP (CREB-binding protein) functions as the crotonyltransferase writing K420 crotonylation on ENO1, and SIRT2 acts as the decrotonylase. ENO1 K420 Kcr enhances ENO1 enzymatic activity and promotes cancer cell growth, migration, and invasion. Mass spectrometry-based crotonylomics, in vitro crotonylation assay, site-directed mutagenesis at K420, functional cell assays Biochemical and biophysical research communications High 34547627
2022 NEDD4L (an E3 ubiquitin ligase) binds ENO1 and promotes its ubiquitination and proteasomal degradation, thereby suppressing glycolysis and cell proliferation in oral squamous cell carcinoma. ENO1 overexpression reverses NEDD4L-mediated suppression. UbiBrowser computational prediction validated by Co-IP, ubiquitination assay, rescue experiments with ENO1 overexpression, in vivo mouse tumor model Cancer biology & therapy Medium 35316145
2020 USP46, a deubiquitinating enzyme, directly stabilizes ENO1 protein by removing ubiquitin modifications, thereby promoting ESCC cell migration, invasion, and metastasis via the EMT process. Co-immunoprecipitation, deubiquitination assay, knockdown functional studies, in vivo metastasis model Experimental cell research Medium 32707136
2024 USP21 directly interacts with and deubiquitinates ENO1 through K48-linked deubiquitination, stabilizing ENO1 protein to promote aerobic glycolysis and cholangiocarcinoma cell proliferation. Co-immunoprecipitation, ubiquitination/deubiquitination assay, in vitro and in vivo functional assays International journal of biological sciences Medium 38385089
2022 The m6A methyltransferase METTL3 methylates ENO1 mRNA at adenosine 359 (359A), which facilitates binding of the m6A reader YTHDF1 to ENO1 mRNA, resulting in enhanced ENO1 translation and increased glycolysis in lung adenocarcinoma. m6A site mapping, RNA immunoprecipitation, YTHDF1-ENO1 mRNA interaction assay, translation efficiency measurement, in vitro and in vivo functional assays Journal of experimental & clinical cancer research High 35078505
2021 C5aR1-positive neutrophil-secreted IL1β and TNFα activate ERK1/2 signaling, which phosphorylates WTAP at serine 341 to stabilize WTAP protein. Stabilized WTAP promotes m6A methylation of ENO1 mRNA, enhancing ENO1 expression and breast cancer glycolysis. m6A methylation assay, WTAP phosphorylation assay, RNA immunoprecipitation, in vitro and in vivo functional assays, co-culture models Cell death & disease Medium 34312368
2024 The NSUN2/YBX1 axis writes and reads m5C modification on ENO1 mRNA respectively: NSUN2 methylates ENO1 mRNA (m5C writer) and YBX1 reads m5C on ENO1 mRNA to upregulate ENO1 expression in an m5C-dependent manner, promoting glucose metabolism reprogramming in colorectal cancer. Lactic acid derived from cancer cells activates NSUN2 transcription via H3K18 lactylation and induces NSUN2 K356 lactylation to enhance target RNA capture. m5C methylation assays, RNA immunoprecipitation, chromatin immunoprecipitation, Co-IP, functional rescue experiments Advanced science Medium 38769664
2024 RBM15/METTL3 complex enhances m6A modification at the 359A site of ENO1 mRNA, promoting ENO1 protein translation efficiency in a YTHDF1-dependent manner in bladder cancer. TGF-β activates RBM15/METTL3 via Smad2/3. ENO1 in turn augments PCNA protein stability by reducing K48-linked ubiquitination of PCNA, preventing its ER-associated degradation. m6A site mapping, RNA immunoprecipitation, co-immunoprecipitation, ubiquitination assay, in vitro and in vivo functional assays Cancer letters Medium 38823761
2020 Exosome-derived ENO1 can be transferred between hepatocellular carcinoma cells via exosome-mediated crosstalk. Transferred ENO1 upregulates integrin α6β4 expression and activates the FAK/Src-p38MAPK pathway in recipient cells, promoting HCC growth and metastasis. Exosome isolation and transfer experiments, Western blotting, Co-IP, functional invasion/migration assays, in vivo xenograft model Cell death & disease Medium 33184263
2018 WBP2 interacts with ENO1 (identified by MS/GST pulldown) and modulates ENO1 glycolysis activity via the ENO1-PI3K/Akt signaling pathway to promote glioma cell proliferation and migration. MS/GST pulldown assay, Co-immunoprecipitation, knockdown functional studies, in vitro and in vivo glioma models Cell death & disease Medium 29497031
2020 FGFRL1 physically interacts with ENO1 and regulates ENO1 expression and downstream PI3K/Akt signaling in small-cell lung cancer, mediating chemoresistance. Co-immunoprecipitation, knockdown/overexpression functional studies, signaling pathway analysis Journal of cellular and molecular medicine Low 31957179
2015 ENO1 and PDIA3 are required for Wnt/β-catenin-driven trans-differentiation of murine alveolar type II epithelial cells to type I cells. siRNA-mediated knockdown of ENO1 in primary ATII cells reduces T1α (ATI cell marker) expression, indicating diminished trans-differentiation. ENO1 expression increases during ATII-to-ATI trans-differentiation and is decreased upon pharmacological Wnt/β-catenin inhibition. Proteomics/mass spectrometry, siRNA knockdown, immunoblotting, primary cell culture, in vivo bleomycin lung injury model Disease models & mechanisms Medium 26035385
2008 Retinoic acid (RA) dephosphorylates the ENO1-A1 phosphoprotein isoform in follicular thyroid carcinoma cells, leading to downregulation of ENO1/MBP-1 gene products. RA-mediated and siRNA-mediated knockdown of ENO1/MBP-1 both reduce MYC oncoprotein levels and decrease proliferation of thyroid carcinoma cells. 2D-DIGE, mass spectrometry, Western blotting, siRNA knockdown, proliferation assays Journal of molecular endocrinology Medium 19060179
2020 Cinnamaldehyde (CA) covalently binds to ENO1 protein, destabilizes ENO1, and inhibits its glycolytic activity. Target identification was performed by chemical biology methods using an alkynyl-CA probe, molecular imaging, and live cell tracing. Activity-based protein profiling with alkynyl-CA probe, molecular imaging, live cell tracing, glycolysis assays, in vivo melanoma model Cancers Medium 32013122
2024 Chlorogenic acid (CGA) covalently binds to ENO1 (identified by activity-based protein profiling) and suppresses ENO1 enzymatic activity, blocking the glycolytic pathway and thereby preventing UVA-induced cellular senescence in human dermal fibroblasts. Activity-based protein profiling (ABPP), co-immunoprecipitation, ENO1 activity assay, glycolysis measurement, photoaging mouse model with proteomics Aging cell Medium 39741388
2025 Interleukin 1 receptor 2 (IL1R2) physically binds ENO1 in macrophages and suppresses its enzymatic activity, thereby inhibiting glycolysis, GSDMD-mediated pyroptosis, and inflammation. IL1R2-deficient mice show heightened sepsis susceptibility that is partially rescued by ENO1 inhibition. Proteomic screening, co-immunoprecipitation, ENO1 enzymatic activity assay, genetic mouse models (IL1R2 KO), ENO1 inhibitor treatment, in vivo sepsis model Advanced science High 40704655
2023 ENO1 binds to the 3'UTR of KLF2 mRNA to stabilize it, increasing KLF2 protein expression and suppressing NLRP3 inflammasome-mediated pyroptosis. ENO1 also binds to the 3'UTR of FUS mRNA to promote FUS expression and circFndc3b cyclization. This was identified in the context of exercise-induced neuroprotection in stroke. RNA immunoprecipitation, mRNA stability assay, functional knockdown/overexpression experiments, in vivo MCAO mouse model Advanced science Medium 39467260
2022 ENO1 binds to ApoC3 (apolipoprotein C-III) in oral squamous cell carcinoma cells (identified by MS/GST pulldown). This interaction elicits IL-8 production; IL-8 activates STAT3 signaling in T cells, promoting T cell apoptosis and inhibiting T cell proliferation. MS/GST pulldown assay, cytokine antibody assay, co-culture experiments, Western blot for STAT3/p-STAT3 International journal of molecular sciences Low 36361568
2024 ENO1 acts as an RNA-binding protein in gastric cancer cells, stabilizing the mRNAs of SOX9, VEGFA, GPRC5A, and MCL1 by binding to them, and interacting with NEAT1, LINC00511, CD44, and PKM2 to regulate their expression, thereby promoting cell proliferation, migration, and inhibiting apoptosis. RNA immunoprecipitation sequencing (RIP-seq), RNA sequencing, bioinformatics analysis Journal of gastrointestinal oncology Medium 37201055
2020 ENO1 promotes lung cancer stem cell self-renewal and invasion by inactivating the AMPK pathway and activating the mTOR pathway. ENO1 was identified as the cell-surface target antigen of monoclonal antibody 12C7 by LC-MALDI-TOF/TOF mass spectrometry and immunoprecipitation. LC-MALDI-TOF/TOF mass spectrometry, immunoprecipitation, immunofluorescence, RNA-seq, KEGG pathway analysis, immunoblot for AMPK/mTOR pathway Stem cell research & therapy Medium 33579362
2024 UCHL3 deubiquitinase stabilizes ENO1 protein through its deubiquitinating enzyme activity in TP53-mutant colorectal cancer. The JAK2-STAT3 pathway controls UCHL3 expression; pacritinib (JAK2 inhibitor) suppresses UCHL3, reducing ENO1 stability and glycolysis. Co-immunoprecipitation, deubiquitination assay, knockdown/overexpression, in vitro and in vivo functional assays, pharmacological inhibition Acta pharmaceutica Sinica. B Medium 40487654
2023 ENO1 upregulates PD-L1 expression in pancreatic ductal adenocarcinoma cells through the HIF-1α signaling pathway, thereby preventing CD8+ T cell infiltration and promoting immune evasion. CRISPR/Cas9 ENO1 knockout, flow cytometry, in vivo mouse PDAC models, mechanistic pathway analysis Translational oncology Medium 39752908
2019 ENO1 silencing in ENO1-deleted glioma cells establishes the concept of collateral lethality: small-molecule enolase inhibitor POMHEX selectively kills ENO1-deleted glioma cells and eradicates intracranial orthotopic ENO1-deleted tumors in mice, demonstrating ENO1 as a glycolytic enzyme whose loss creates dependency on ENO2. In vitro cell killing assays, intracranial orthotopic xenograft mouse model, pharmacokinetic studies in non-human primates Nature metabolism High 33230295
2022 ENO1 promotes OSCC tumor cell migration and invasion through a dual mechanism: (1) tumor cell-derived lactic acid (produced via ENO1-mediated glycolysis) activates macrophages to secrete IL-6, and (2) paracrine ENO1 signals through TLR4 on macrophages to further stimulate IL-6 secretion. IL-6 in turn promotes tumor cell EMT and invasion in a positive feedback loop. siRNA knockdown, recombinant ENO1 stimulation, conditioned medium experiments, cytokine measurement, EMT marker analysis International journal of molecular sciences Medium 36614179
2023 Extracellular ENO1 (surface or secreted form) enhances glycolysis by upregulating HIF-1α and glycolysis-related gene expression in multiple myeloma cells. ENO1-specific monoclonal antibody blocks these extracellular ENO1-mediated effects and reduces tumor growth in an MM xenograft model. ENO1 knockdown, addition of recombinant extracellular ENO1 protein, HIF-1α silencing, glycolysis assays, Seahorse analysis, in vivo MM xenograft model with ENO1 mAb Oncology reports Medium 37800625
2023 In hepatic stellate cells, the FAK/Ras/c-myc/ENO1 pathway promotes aerobic glycolysis and liver fibrosis. Chromatin immunoprecipitation and dual-luciferase reporter assays validated that c-myc binds the ENO1 promoter to drive ENO1 transcription in this context. ChIP, dual-luciferase reporter assay, FRNK knockout mouse model, in vitro LX-2 cell experiments, glycolysis measurements World journal of gastroenterology Medium 35125823
2024 ENO1 mRNA is acetylated at N4-cytidine (ac4C) by NAT10 (N-acetyltransferase 10), which enhances ENO1 mRNA stability and translation. NAT10 inhibition reduces ac4C levels on ENO1 mRNA, decreasing ENO1 expression and thereby inhibiting glycolysis and promoting apoptosis in NSCLC cells. ac4C-RNA immunoprecipitation (acRIP), dual-luciferase reporter assay, ENO1 overexpression rescue experiments, glycolysis and apoptosis assays BMC pulmonary medicine Medium 39948547
2022 The lncRNA AL355338 directly binds ENO1 protein, enhances its stability by modulating ubiquitination and degradation, and enables ENO1/EGFR complex formation to activate EGFR-AKT signaling and promote NSCLC glycolysis and progression. RNA pull-down, mass spectrometry, RNA immunoprecipitation (RIP), co-immunoprecipitation, in situ proximity ligation assay, ubiquitination assay Cancer cell international Medium 34627260
2023 ENO1 promotes hypoxia-induced ERK phosphorylation in pancreatic ductal adenocarcinoma cells, thereby inhibiting apoptosis and promoting tumor survival and invasion. Under hypoxic conditions, CoCl2-treated ENO1-knockdown cells show elevated caspase-3 and increased apoptosis, reversing the hypoxia-induced ERK signaling. Transcriptomic sequencing, ENO1 knockdown, ERK phosphorylation assay, apoptosis assay, in vivo PDAC hindlimb ischemia model Cancer biology & medicine Medium 36476328
2024 ENO1 deletion in colorectal cancer cells inactivates AKT/STAT3 signaling, which leads to decreased glycolysis and enhanced ferroptosis. AKT activator SC79 partially reverses the effects of ENO1 deficiency on glycolysis, proliferation, and ferroptosis, placing ENO1 upstream of the AKT/STAT3 axis. CRISPR-based ENO1 knockdown, AKT activator rescue (SC79), glycolysis measurement, ferroptosis markers, cell proliferation assays Experimental and therapeutic medicine Medium 38414789
2023 ENO1 promotes gemcitabine resistance in pancreatic cancer by maintaining expression of YAP1 (a Hippo pathway effector), which promotes autophagy and protects cells from gemcitabine-induced apoptosis. YAP1 overexpression attenuates the inhibitory effects of ENO1 silencing. ENO1 knockdown, YAP1 overexpression rescue, autophagy assays (TEM, flow cytometry), in vivo tumor growth model, immunoblot Molecular carcinogenesis Medium 38517039
2021 CircNFKB1 physically interacts with ENO1, and this interaction regulates expression of the parental gene NFKB1 to sustain NF-κB signaling pathway activation in chondrocytes, promoting osteoarthritis progression. circRNA sequencing, RNA pulldown, co-immunoprecipitation, NF-κB signaling assays, intra-articular injection mouse model Cell death & disease Medium 35945200
2024 LINC00520 lncRNA binds ENO1 protein and blocks FBXW7-mediated ubiquitination and proteasomal degradation of ENO1, thereby stabilizing ENO1 to promote glycolysis and cisplatin resistance in osteosarcoma. Co-immunoprecipitation, ubiquitination assay, rescue experiments, in vitro and in vivo functional assays Cancer letters Medium 39168299
2019 ENO1 expression promotes β-catenin expression in bladder cancer cells. Ectopic β-catenin overexpression rescues proliferation impaired by ENO1 knockdown, and β-catenin knockdown phenocopies ENO1 knockdown, establishing ENO1 as an upstream regulator of β-catenin in bladder cancer. Lentivirus-mediated knockdown and overexpression, β-catenin rescue experiments, double knockdown, cell proliferation/growth assays Bioscience reports Low 31431517
2023 Targeting endothelial ENO1 via siRNA or inhibitor restores hypoxia-induced endothelial dysfunction (excessive proliferation, angiogenesis, adhesion). RNA-seq showed ENO1 targets mitochondrion-related genes and the PI3K-Akt signaling pathway in endothelial cells. Adeno-associated virus overexpressing ENO1 worsens hypoxic pulmonary hypertension. siRNA knockdown, ENO1 inhibitor, AAV-ENO1 delivery in vivo, RNA-seq, Seahorse mitochondrial function analysis, mouse pulmonary hypertension model Hypertension Medium 37075135
2024 Disturbed shear stress (DS) induces ENO1 expression in vascular endothelial cells. ENO1 silencing represses DS- and TGF-β-induced endothelial inflammation and endothelial-to-mesenchymal transition (EndMT). ENO1 is highly expressed in ECs at the proatherogenic inner curvature of the mouse aortic arch in vivo. Single-cell RNA sequencing, pseudotime trajectory analysis, ENO1 siRNA knockdown with shear stress/TGF-β stimulation, in vivo mouse aortic arch analysis Proceedings of the National Academy of Sciences Medium 38261622
2021 ENO1 promotes invasion and metastasis in Burkitt lymphoma by acting as a plasminogen receptor that recruits plasminogen (PLG), promoting plasmin generation and TGF-β1 activation, which activates PI3K-AKT and EMT signaling pathways. A natural compound (Ciwujianoside E/L-06) disrupts the ENO1-PLG interaction and reduces tumor growth. RNA interference, Co-IP/ENO1-PLG interaction assay, plasmin activity assay, TGF-β1 activation measurement, in vitro and in vivo functional assays Biomedicine & pharmacotherapy Medium 38897160
2023 ENO1, acting as an RNA-binding protein, binds to the 3'UTR of Klf2 mRNA to stabilize it; KMT5A (H4K20 methyltransferase) and RFX1 transcription factor associate with the ENO1 promoter to regulate its transcription in diabetic nephropathy. High glucose downregulates KMT5A and increases RFX1, leading to elevated ENO1 expression and endothelial-to-mesenchymal transition. ChIP, promoter activity assay, siRNA knockdown, Co-immunoprecipitation between KMT5A and RFX1, in vivo DN mouse and patient samples International journal of biological sciences Medium 34803485

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2000 ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS letters 234 10802057
2020 F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. Gut 227 33318144
2019 CircRNA-ENO1 promoted glycolysis and tumor progression in lung adenocarcinoma through upregulating its host gene ENO1. Cell death & disease 208 31767835
2021 ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1. Nature cancer 172 35121990
2022 ENO1 and Cancer. Molecular therapy oncolytics 156 35434271
2024 Metabolic Recoding of NSUN2-Mediated m5C Modification Promotes the Progression of Colorectal Cancer via the NSUN2/YBX1/m5C-ENO1 Positive Feedback Loop. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 150 38769664
2021 ENO1 Promotes Lung Cancer Metastasis via HGFR and WNT Signaling-Driven Epithelial-to-Mesenchymal Transition. Cancer research 122 34145039
2017 Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. Journal of hematology & oncology 116 28086938
2013 Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology 110 23333712
2022 The essential roles of m6A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma. Journal of experimental & clinical cancer research : CR 100 35078505
2020 Exosome-derived ENO1 regulates integrin α6β4 expression and promotes hepatocellular carcinoma growth and metastasis. Cell death & disease 89 33184263
2021 C5aR1-positive neutrophils promote breast cancer glycolysis through WTAP-dependent m6A methylation of ENO1. Cell death & disease 87 34312368
2017 Alpha-Enolase (ENO1), a potential target in novel immunotherapies. Frontiers in bioscience (Landmark edition) 84 27814656
2023 ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism. Nature chemical biology 71 37500770
2020 An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nature metabolism 68 33230295
2019 Expression of Alpha-Enolase (ENO1), Myc Promoter-Binding Protein-1 (MBP-1) and Matrix Metalloproteinases (MMP-2 and MMP-9) Reflect the Nature and Aggressiveness of Breast Tumors. International journal of molecular sciences 67 31416219
2015 FBXW7 negatively regulates ENO1 expression and function in colorectal cancer. Laboratory investigation; a journal of technical methods and pathology 64 26097998
2022 PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism. Acta pharmaceutica Sinica. B 60 36815049
2023 Targeting Endothelial ENO1 (Alpha-Enolase) -PI3K-Akt-mTOR Axis Alleviates Hypoxic Pulmonary Hypertension. Hypertension (Dallas, Tex. : 1979) 56 37075135
2015 ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas. Experimental cell research 55 26024773
2015 Enolase 1 (ENO1) and protein disulfide-isomerase associated 3 (PDIA3) regulate Wnt/β-catenin-driven trans-differentiation of murine alveolar epithelial cells. Disease models & mechanisms 55 26035385
2018 WW domain-binding protein 2 acts as an oncogene by modulating the activity of the glycolytic enzyme ENO1 in glioma. Cell death & disease 53 29497031
2010 Regulation of cortical contractility and spindle positioning by the protein phosphatase 6 PPH-6 in one-cell stage C. elegans embryos. Development (Cambridge, England) 47 20040490
2021 Upregulation of α enolase (ENO1) crotonylation in colorectal cancer and its promoting effect on cancer cell metastasis. Biochemical and biophysical research communications 46 34547627
2018 ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance. Gastroenterology research and practice 45 29483925
2020 Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma. Oncogene 44 32024967
2020 FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1. Journal of cellular and molecular medicine 41 31957179
2019 Hyperglycemia promotes Snail-induced epithelial-mesenchymal transition of gastric cancer via activating ENO1 expression. Cancer cell international 41 31889896
2021 KMT5A downregulation participated in High Glucose-mediated EndMT via Upregulation of ENO1 Expression in Diabetic Nephropathy. International journal of biological sciences 39 34803485
2018 The Candida albicans ENO1 gene encodes a transglutaminase involved in growth, cell division, morphogenesis, and osmotic protection. The Journal of biological chemistry 39 29386353
2024 Single-cell RNA sequencing unveils unique transcriptomic signatures of endothelial cells and role of ENO1 in response to disturbed flow. Proceedings of the National Academy of Sciences of the United States of America 38 38261622
2022 NEDD4L inhibits glycolysis and proliferation of cancer cells in oral squamous cell carcinoma by inducing ENO1 ubiquitination and degradation. Cancer biology & therapy 37 35316145
2022 Circular RNA circNFKB1 promotes osteoarthritis progression through interacting with ENO1 and sustaining NF-κB signaling. Cell death & disease 36 35945200
2020 Circular RNA circSEMA5A promotes bladder cancer progression by upregulating ENO1 and SEMA5A expression. Aging 35 33176280
2008 Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines. Journal of molecular endocrinology 32 19060179
2023 Melatonin inhibits bladder tumorigenesis by suppressing PPARγ/ENO1-mediated glycolysis. Cell death & disease 30 37024456
2022 Baicalein Acts against Candida albicans by Targeting Eno1 and Inhibiting Glycolysis. Microbiology spectrum 30 35900099
2024 Role of ENO1 and its targeted therapy in tumors. Journal of translational medicine 28 39543641
2023 PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1. MedComm 28 36999124
2019 Up-regulated ENO1 promotes the bladder cancer cell growth and proliferation via regulating β-catenin. Bioscience reports 28 31431517
2022 FAM126A interacted with ENO1 mediates proliferation and metastasis in pancreatic cancer via PI3K/AKT signaling pathway. Cell death discovery 27 35513377
2010 MBP-1 is efficiently encoded by an alternative transcript of the ENO1 gene but post-translationally regulated by proteasome-dependent protein turnover. The FEBS journal 27 20849415
2024 USP21 deubiquitinates and stabilizes HSP90 and ENO1 to promote aerobic glycolysis and proliferation in cholangiocarcinoma. International journal of biological sciences 26 38385089
2024 METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1. Cancer letters 26 39168299
2020 CircZNF609 aggravates neuropathic pain via miR-22-3p/ENO1 axis in CCI rat models. Gene 25 32827683
2020 ENO1-targeted superparamagnetic iron oxide nanoparticles for detecting pancreatic cancer by magnetic resonance imaging. Journal of cellular and molecular medicine 23 32285549
2020 Silencing of ENO1 inhibits the proliferation, migration and invasion of human breast cancer cells. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 23 32521855
2020 Ubiquitin-specific peptidase 46 promotes tumor metastasis through stabilizing ENO1 in human esophageal squamous cell carcinoma. Experimental cell research 23 32707136
2014 Effects of skin-to-skin contact and breastfeeding at birth on the incidence of PPH: A physiologically based theory. Women and birth : journal of the Australian College of Midwives 23 25113818
2024 N6-Methyladenosine enhances the translation of ENO1 to promote the progression of bladder cancer by inhibiting PCNA ubiquitination. Cancer letters 22 38823761
2023 ENO1 Promotes OSCC Migration and Invasion by Orchestrating IL-6 Secretion from Macrophages via a Positive Feedback Loop. International journal of molecular sciences 22 36614179
2023 N6-methyladenosine methyltransferase KIAA1429 promoted ovarian cancer aerobic glycolysis and progression through enhancing ENO1 expression. Biology direct 22 37807062
2022 Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway. World journal of gastroenterology 22 35125823
2021 Alpha-enolase (ENO1), identified as an antigen to monoclonal antibody 12C7, promotes the self-renewal and malignant phenotype of lung cancer stem cells by AMPK/mTOR pathway. Stem cell research & therapy 22 33579362
2020 Cinnamaldehyde Enhances Antimelanoma Activity through Covalently Binding ENO1 and Exhibits a Promoting Effect with Dacarbazine. Cancers 22 32013122
1993 Linkage relationships between ALPL, ENO1, GPI, PGD, and TGFB1 on porcine chromosome 6. Genomics 22 8104872
2023 Enhanced E6AP-mediated ubiquitination of ENO1 via LINC00663 contributes to radiosensitivity of breast cancer by regulating mitochondrial homeostasis. Cancer letters 20 36871813
2022 ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway. Frontiers in oncology 20 36620599
2018 Silencing of ENO1 by shRNA Inhibits the Proliferation of Gastric Cancer Cells. Technology in cancer research & treatment 20 29986635
2024 CircFndc3b Mediates Exercise-Induced Neuroprotection by Mitigating Microglial/Macrophage Pyroptosis via the ENO1/KLF2 Axis in Stroke Mice. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 19 39467260
2023 Unrevealed roles of extracellular enolase‑1 (ENO1) in promoting glycolysis and pro‑cancer activities in multiple myeloma via hypoxia‑inducible factor 1α. Oncology reports 19 37800625
2023 Knockout of ENO1 leads to metabolism reprogramming and tumor retardation in pancreatic cancer. Frontiers in oncology 18 36845730
2023 Beyond ENO1, emerging roles and targeting strategies of other enolases in cancers. Molecular therapy oncolytics 18 38075246
2018 A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth. EBioMedicine 18 30527624
2024 ENO1 deletion potentiates ferroptosis and decreases glycolysis in colorectal cancer cells via AKT/STAT3 signaling. Experimental and therapeutic medicine 17 38414789
2020 The circ-AMOTL1/ENO1 Axis Implicated in the Tumorigenesis of OLP-Associated Oral Squamous Cell Carcinoma. Cancer management and research 17 32884340
2022 TRPC5OS induces tumorigenesis by increasing ENO1-mediated glucose uptake in breast cancer. Translational oncology 16 35584604
2021 AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC. Cancer cell international 16 34627260
2020 Gold Drugs with {Au(PPh3 )}+ Moiety: Advantages and Medicinal Applications. ChemMedChem 16 33025735
2017 Peripartum Haemorrhage: Haemostatic Aspects of the New German PPH Guideline. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 16 29765296
2025 ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling. Translational oncology 15 39752908
2010 [ENO1 protein levels in the tumor tissues and circulating plasma samples of non-small cell lung cancer patients]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 15 21159241
2000 Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma. International journal of oncology 15 10853020
1997 Chromosomal localization of the human gene encoding c-myc promoter-binding protein (MPB1) to chromosome 1p35-pter. Genomics 15 9119380
2024 ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway. Molecular carcinogenesis 14 38517039
2024 Identifying ENO1 as a protein target of chlorogenic acid to inhibit cellular senescence and prevent skin photoaging in mice. Aging cell 14 39741388
2021 EGR1 modulated LncRNA HNF1A-AS1 drives glioblastoma progression via miR-22-3p/ENO1 axis. Cell death discovery 14 34772911
2007 Multiple basic helix-loop-helix proteins regulate expression of the ENO1 gene of Saccharomyces cerevisiae. Eukaryotic cell 14 17351075
2007 SMK-1/PPH-4.1-mediated silencing of the CHK-1 response to DNA damage in early C. elegans embryos. The Journal of cell biology 14 17908915
2025 Targeting the JAK2-STAT3-UCHL3-ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer. Acta pharmaceutica Sinica. B 13 40487654
2024 ARNTL2 facilitates bladder cancer progression through potentiating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner. Life sciences 13 39147318
2022 Linc-UROD stabilizes ENO1 and PKM to strengthen glycolysis, proliferation and migration of pancreatic cancer cells. Translational oncology 13 36413861
2021 ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells. American journal of cancer research 13 34094663
2024 Marrow mesenchymal stem cell mediates diabetic nephropathy progression via modulation of Smad2/3/WTAP/m6A/ENO1 axis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 12 38847786
2022 Lactate promotes the growth of patient-derived organoids from hepatopancreatobiliary cancers via ENO1/HIF1α pathway and does not affect their drug sensitivities. Cell death discovery 12 35443744
2022 ENO1 Binds to ApoC3 and Impairs the Proliferation of T Cells via IL-8/STAT3 Pathway in OSCC. International journal of molecular sciences 12 36361568
2022 ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment. Cancer biology & medicine 12 36476328
2006 Metabolism of 2-, 3- and 4-hydroxybenzoates by soil isolates Alcaligenes sp. strain PPH and Pseudomonas sp. strain PPD. FEMS microbiology letters 12 17169001
2025 Role of NAT10-mediated ac4C acetylation of ENO1 mRNA in glycolysis and apoptosis in non-small cell lung cancer cells. BMC pulmonary medicine 11 39948547
2024 Ciwujianoside E inhibits Burkitt lymphoma cell proliferation and invasion by blocking ENO1-plasminogen interaction and TGF-β1 activation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 11 38897160
2024 Kinetics and Mechanism of PPh3/Ni-Catalyzed, Zn-Mediated, Aryl Chloride Homocoupling: Antagonistic Effects of ZnCl2/Cl. Journal of the American Chemical Society 11 39420638
2023 ENO1 promotes immunosuppression and tumor growth in pancreatic cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 11 36820953
2025 Critical Role of IL1R2-ENO1 Interaction in Inhibiting Glycolysis-Mediated Pyroptosis for Protection Against Lethal Sepsis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10 40704655
2025 FIGO good practice recommendations on anemia in pregnancy, to reduce the incidence and impact of postpartum hemorrhage (PPH). International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 10 41031541
2025 CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis. Journal of experimental & clinical cancer research : CR 9 39980052
2023 RNA-binding protein ENO1 promotes the tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes. Journal of gastrointestinal oncology 9 37201055
2022 Alpha-Enolase (ENO1) Correlates with Invasiveness of Cutaneous Melanoma-An In Vitro and a Clinical Study. Diagnostics (Basel, Switzerland) 9 35204345
2022 Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers. Journal of medicinal chemistry 9 36251833
2019 Targetting an LncRNA P5848-ENO1 axis inhibits tumor growth in hepatocellular carcinoma. Bioscience reports 9 30541900
2014 Molecular characterisation and expression profiling of the ENO1 gene in the ovarian follicle of the Sichuan white goose. Molecular biology reports 9 24413993

Missed literature

Know a paper Affinage missed for ENO1? Flag it for the maintainers and the community.

No submissions yet.